朊病毒疾病治疗市场－全球产业规模、份额、趋势、机会及预测，依类型（人类朊病毒疾病、动物朊病毒疾病）、药物（抗忧郁药物、抗精神病药物）、地区及竞争细分，2020-2030 年预测

2024 年全球朊病毒疾病治疗市值为 49.7 亿美元，预计到 2030 年将达到 64.7 亿美元，预测期内复合年增长率为 4.49%。朊病毒病，又称传染性海绵状脑病 (TSE)，是一种罕见的致命神经退化性疾病，由大脑中错误折迭的朊病毒蛋白的异常积累引起。这些疾病包括克雅氏症 (CJD)、变异型克雅氏症 (vCJD)、致死性家族性失眠症 (FFI) 等。在疾病意识增强、诊断方法改进以及旨在开发有效疗法的研究措施增加的支持下，市场正在稳步扩张。虽然无法治愈，但目前的治疗方法主要是支持性的，重点在于症状管理和患者的生活品质。人类朊病毒疾病占主导地位，受较高盛行率和研究活动的推动。抗忧郁药物因其在控制神经和精神症状方面的作用而成为领先的药物类别。儘管存在诊断复杂性、发病率低和治疗选择有限等挑战，但生物标记研究的创新、神经退化研究的资金以及先进治疗方法的探索预计将进一步推动市场成长。

关键市场驱动因素

朊病毒疾病的盛行率不断上升

主要市场挑战

对朊病毒疾病的了解有限

主要市场趋势

新兴治疗方法

• 正在开发小分子来破坏朊病毒复製并降低神经毒性。
• 人们正在探索单株抗体结合和中和错误折迭的朊病毒蛋白的潜力。
• 基于 RNA 的疗法，例如反义寡核苷酸 (ASO) 和 RNA 干扰 (RNAi)，旨在抑制异常朊病毒蛋白的产生或促进其分解。
• 包括 CRISPR-Cas9 在内的基因治疗技术有望纠正导致遗传性朊病毒疾病的基因突变。

这些治疗创新虽然主要处于实验阶段，但为未来的疾病改良治疗带来了希望，并吸引了越来越多的投资和研究关注。

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球朊病毒疾病治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（人类朊病毒疾病、动物朊病毒疾病）
  • 按药物（抗忧郁药、抗精神病药）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美朊病毒疾病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲朊病毒疾病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太朊病毒疾病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美朊病毒疾病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲朊病毒疾病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球朊病毒疾病治疗市场：SWOT 分析

第 14 章：竞争格局

• Fresenius SE & Co. KGaA
• Elite Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Novartis AG
• Merck KGaA
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Cipla Ltd
• Teva Pharmaceuticals
• Abbott Laboratories

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Prion Disease Treatment Market was valued at USD 4.97 Billion in 2024 and is projected to reach USD 6.47 Billion by 2030, growing at a CAGR of 4.49% during the forecast period. Prion diseases, or transmissible spongiform encephalopathies (TSEs), are rare, fatal neurodegenerative disorders resulting from the abnormal accumulation of misfolded prion proteins in the brain. These include conditions such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and others. The market is witnessing steady expansion, supported by greater disease awareness, improved diagnostics, and increased research initiatives aimed at developing effective therapies. While no cure exists, current treatment approaches are largely supportive, focusing on symptom management and patient quality of life. Human prion diseases are the dominant segment, driven by higher prevalence and research activity. Antidepressants represent the leading drug class due to their role in managing neurological and psychiatric symptoms. Innovations in biomarker research, funding for neurodegenerative studies, and exploration of advanced therapeutic methods are expected to further propel market growth, despite challenges such as diagnostic complexity, low incidence rates, and limited treatment options.

Key Market Drivers

Increasing Prevalence of Prion Diseases

The rising incidence of prion diseases globally is a major growth driver for the treatment market. These neurodegenerative disorders, though rare, are increasingly diagnosed due to advancements in medical technology and growing awareness among healthcare professionals. Enhanced diagnostic capabilities have made it possible to identify cases that were previously misdiagnosed or undetected, contributing to a perceived rise in prevalence. Additionally, the aging global population has amplified the incidence of diseases like sporadic CJD, which is more common in older adults. According to the National Library of Medicine, at least 485 cases of iatrogenic CJD (iCJD) have been documented worldwide, most of which occurred prior to 2012. These included cases linked to contaminated surgical tools, EEG needles, corneal transplants, and notably, human-derived growth hormones and dura mater grafts. As detection improves and awareness increases, the demand for prion disease treatments is expected to grow steadily.

Key Market Challenges

Limited Understanding of Prion Diseases

A major challenge hindering the development of effective prion disease therapies is the limited understanding of the diseases' underlying mechanisms. Prion disorders are complex, and their pathogenesis-particularly how prions replicate and cause neurodegeneration-remains only partially understood. This knowledge gap restricts the identification of viable drug targets and slows down therapeutic innovation. The intricacy of prion biology requires extensive research to unravel molecular pathways before advancing drug discovery. This lack of foundational understanding poses a significant barrier to the timely development and approval of effective treatments.

Key Market Trends

Emerging Therapeutic Approaches

Innovative treatment strategies are emerging as key trends in the prion disease treatment landscape. Researchers are investigating a range of novel approaches to halt or reverse disease progression.

• Small molecules are being developed to disrupt prion replication and reduce neurotoxicity.
• Monoclonal antibodies are being explored for their potential to bind and neutralize misfolded prion proteins.
• RNA-based therapies, such as antisense oligonucleotides (ASOs) and RNA interference (RNAi), aim to suppress abnormal prion protein production or promote its breakdown.
• Gene therapy techniques, including CRISPR-Cas9, show promise for correcting genetic mutations responsible for inherited prion disorders.

These therapeutic innovations, though largely in experimental phases, offer hope for disease-modifying treatments in the future and are attracting increasing investment and research attention.

Key Market Players

• Fresenius SE & Co. KGaA
• Elite Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Novartis AG
• Merck KGaA
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Cipla Ltd
• Teva Pharmaceuticals
• Abbott Laboratories

Report Scope:

In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prion Disease Treatment Market, By Type:

• Human Prion Diseases
• Animal Prion Diseases

Prion Disease Treatment Market, By Drug:

• Antidepressant
• Antipsychotic Agents

Prion Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.

Available Customizations:

Global Prion Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prion Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
  • 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Prion Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prion Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug
  • 6.3.2. Canada Prion Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug
  • 6.3.3. Mexico Prion Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug

7. Europe Prion Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prion Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug
  • 7.3.2. United Kingdom Prion Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug
  • 7.3.3. Italy Prion Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug
  • 7.3.4. France Prion Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug
  • 7.3.5. Spain Prion Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug

8. Asia-Pacific Prion Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Prion Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug
  • 8.3.2. India Prion Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug
  • 8.3.3. Japan Prion Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug
  • 8.3.4. South Korea Prion Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug
  • 8.3.5. Australia Prion Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug

9. South America Prion Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Prion Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug
  • 9.3.2. Argentina Prion Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug
  • 9.3.3. Colombia Prion Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug

10. Middle East and Africa Prion Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Prion Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug
  • 10.3.2. Saudi Arabia Prion Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug
  • 10.3.3. UAE Prion Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Prion Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Fresenius SE & Co. KGaA
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Elite Pharmaceuticals Inc
• 14.3. Ionis Pharmaceuticals Inc
• 14.4. Novartis AG
• 14.5. Merck KGaA
• 14.6. AstraZeneca PLC
• 14.7. Bristol-Myers Squibb Company
• 14.8. Cipla Ltd
• 14.9. Teva Pharmaceuticals
• 14.10. Abbott Laboratories

15. Strategic Recommendations

16. About Us & Disclaimer